mdlinx mdlinx
Print

Comparison of the efficacy and safety of paclitaxel-eluting coroflex please stents and paclitaxel-eluting stents in patients with coronary artery disease: A randomized PIPA trial
Catheterization and Cardiovascular Interventions, 04/20/2012

Kim HS et al. – The Coroflex Please stent resulted in similar angiographic and clinical outcomes as the Taxus Liberte stent in patients with coronary artery lesions.

Methods
  • Authors randomly assigned 319 patients to receive Coroflex Please stents (159 patients; 198 lesions) or Taxus Liberte stents (160 patients; 232 lesions).
  • The primary end point was angiographic in–segment late luminal loss at 9 months.

Results
  • Most baseline clinical and angiographic characteristics were similar between these two groups.
  • The Coroflex Please and Taxus Liberte stents showed similar in–segment late loss (0.40 ± 0.53 mm vs. 0.39 ± 0.52 mm, P = 0.98) and rates of in–segment binary restenosis (22.2% vs. 18.8%, P = 0.48) at 9 months.
  • After clinical follow–up for 12 months, the two groups had similar rates of death (1.3% vs. 1.3%, P > 0.99), myocardial infarction (3.8% vs. 7.5%, P = 0.22), stent thrombosis (2.5% vs. 1.9%, P = 0.72), and target–lesion revascularization (7.5% vs. 7.5%, P = 0.99).

Get reports via email to claim your reading activity at MDLinx as Category 2 CME (It takes less than a minute)

Register now to view all the MDLinx contents (FREE)!

  • Stay current on the latest literature, research and clinical news
  • Get special communications and offers from MDLinx and our sponsors
  • Receive invitations to paid market research
View Samples and Register

Stay current - Media Tool

Newsletter
RSS
Follow Us
Facebook

Receive free subspecialty
"5-minute updates" via email

Sign up!

Send the E-mail Newsletter to a Colleague


Send

Subscribe to our free RSS feeds:
Get the latest news in your specialty automatically added to your newsreader or your personal My Yahoo!, Google, My MSN or My AOL page. Learn More

Follow Us on Twitter
Twitter is a rich source of instantly updated information. Join today and follow @MDLinx to start receiving tweets. Learn More

Close